This opening section provides details of the offering

Issuer ......

Offer Type Issue of new shares

Total Offer Size .....equity shares of face value $1 each

Offer Price$10 per share

Total Issue Amount$500 million

ListingNew York Stock Exchange (Ticker: ...)

Lead Managers .....name of the bankers

Registrar to the Issue...... Registrars

Issue OpensMarch 1, 2025

Issue ClosesMarch 5, 2025

Describing risk factors is a very important exercise and can take up a lot of time certainlywhen the company wants to reflect a truly transparent presentation to investors Here are a few :

Dependence on Key Products: A significant portion of our revenue comes from our flagship product ....., making us vulnerable to product-specific risks.

Technological Obsolescence: Rapid technological changes could render our software offerings obsolete.

Competition: We face intense competition from both established multinational firms and emerging start-ups.

Cybersecurity Risks: A major data breach could adversely affect our brand and customer trust.

Regulatory Risks: Compliance with evolving data protection and privacy regulations could increase costs.

NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases.

NMD Pharma has a unique experimental platform focusing on ion channel function and electrophysiology of skeletal muscle. We develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence.